Clinical Research by Disease Site
The Department of Radiation Oncology enrolls as many as 80 new patients each year in clinical trials. Faculty members hold leadership positions in the Radiation Therapy Oncology Group (RTOG), which develops and oversees all national radiation oncology trials funded by the National Cancer Institute.
See current clinical trial information below or contact the Clinical Research office at 214-645-7322.
STU 042018-083: GammaPod 5 fxn - Phase II Multi-Center Trial Evaluating 5 Fraction S-PBI (Stereotactic Partial Breast Irradiation) for Early Stage Breast Cancer Using the GammaPod. Learn about the GammaPod.
STU 052018-052: GammaPod Boost - Tumor Bed Boost Using a Breast-Specific Radiosurgery Device, the GammaPod: Registry Study and Evaluation of Quality of Life with Development of Sizing Nomogram. Learn about the GammaPod.
STU 062015-085: SF CK Breast - Phase I Dose Escalation Trial of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation (SB-PBI) for Early Stage Breast Cancer.
STU 2018-0236: Tailor RT - A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node-Positive Breast Cancer.
STU 2019-1099 28231 - Single Institution Pilot Study to Detect Radiation-Induced Cardiotoxicity in Left-Sided Breast Cancer Patients Using Hyperpolarized Carbon 13-Based Magnetic Resonance Spectroscopic Imaging.
STU 2019-1183 - A Phase I Dose-Escalation Study of Single Fraction Pre-Operative Partial Breast (S-PBI) for Early Stage Breast Cancer.
Central Nervous System
STU 122016-064: Neurocog. Decline - Phase I/II Trial to Determine the Neurocognitive Decline in Patients with Multiple (>6) Brain Metastases Treated with Distributed Stereotactic Radiosurgery.
STU 42011-075: Pituitary - Interstitial Radioactive Iodine Implants for the Treatment of Pan-Invasive Pituitary Macroadenomas.
STU 022015-106: SRS-Dose Escalation - A Phase I Dose-Escalation Study of Stereotactic Radiosurgery for Brain Metastasis without Whole Brain Radiation.
STU 042018-100: AVM - Validation Study of Treating Arteriovenous Malformation with Stereotactic Radiosurgery Using CT Angiography for Treatment Planning.
STU 102014-018: Liver Mets Brachy - A Phase I Therapeutic Dose-Escalation Study Using Percutaneous Image-Guided Navigation for High-Dose Rate Brachyablation of Primary Liver Lesions.
STU 022016-002: CIPHER - A Prospective, Multi-Center Randomized Phase 3 Trial of Carbon Ion Versus Conventional Photon Radiation Therapy for Locally Advanced, Unresectable Pancreatic Cancer.
STU 2019-1492 - Phase II Randomized Multi-Center Trial of Total Neoadjuvant Therapy With and Without CD40 Agonist, APX005M, for Locally Advanced Rectal Adenocarcinoma.
STU 022017-032: NRG-GU002 - Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel.
STU 042016-046: Oligo Metastatic Renal Cell - Phase II Trial of SAbR for Patients with Oligometastatic Renal Cell Carcinoma.
STU 122016-067: Salvenza - Phase II Randomized Placebo-Controlled Double-Blinded Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy (SALV-ENZA).
STU 022015-058: IVC Thrombus - Safety Lead-In Phase II Trial of Neo-Adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC.
STU 052018-001: Oligo-Progressive - A Phase II Trial of Stereotactic Ablative Radiation Therapy (SAbR) for Patients with Oligo-Progressive Renal Cancer (RCC).
STU 092017-018: POTEN-C - Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C): A Phase II Randomized Controlled Trial of Stereotactic Ablative Body Radiotherapy (SAbR) with or without Neurovascular Sparing for Erectile Function Preservation in Localized Prostate Cancer. Learn more about the POTEN-C trial.
STU 2019-1065: RTOG-3506 - STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features.
STU 2019-1506: A Phase II Trial of Stereotactic Ablative Radiation (SAbR) for Urothelial Cancer Patients with Progression while on Anti-PD-1/PD-L1 Immunotherapy.
STU 2018-0151: AZ Durva/Treme SAbR - Phase I Multi-Center Study of Stereotactic Ablative Radiotherapy (SAbR) in Combination with Durvalumab and Tremelimumab in Patients with Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer.
Head and Neck
STU 072014-041: NRG-HN001 - Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA).
STU 122017-043: LT-SABR - A Phase II Trial of Glottic Larynx Stereotactic Ablative Radiotherapy (LT-SABR) for Early Stage Glottic Larynx Cancer.
STU 022011-213: RTOG-1008 - A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors.
STU 2019-0711: INRT-AIR - A Prospective Phase II Study of Involved Nodal Radiation Therapy using Artificial Intelligence-Based Radiomics for Head and Neck Squamous Cell Carcinoma.
STU 2019-0748: IPET - Pilot Study of Interim PET/CT in Patients Treated with Definitive Chemoradiotherapy for Head and Neck Cancer.
STU 2019-1316: RTOG 3507 - KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA) Plus Stereotactic Re-Irradiation versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma.
STU 042017-024: NRG-LU002 - Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Cancer (NSCLC): A Randomized Phase II/III Trial.
STU 022015-069: JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC), the STABLE-MATES Trial.
STU 2018-0261: ADRIATIC - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC).
STU 2019-0858: PACIFIC 4/RTOG-3515 - A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-Small Cell Lung Cancer (PACIFIC-4/RTOG-3515).
STU 2019-1082 - A Phase II Concurrent Durvalumab (MEDI4736) and Radiotherapy Followed by Consolidative Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancer (NSCLC).
STU 062016-073: Lung SAbR - Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereotactic Ablative Body Radiotherapy (SAbR).
STU 022017-075: Vision RT - VisionRT-Based Deep Inspiration Breath-Hold (DIBH) Respiratory Motion Management Strategy, a Pilot Study for Thoracic and Abdominal Tumors Stereotactic Body Radiotherapy.
STU 2019-1390: Tissue Procurement and Outcome Collection for Cancer Patients With and Without Cachexia.
STU 2019-1142: Video-based motion detection and prediction for pediatric radiotherapy.
STU 072010-098: Tissue Procurement - Tissue Procurement and Outcome Collection for Radiotherapy-Treated Patients.